Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04911478Active Not Recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Role: lead

NCT06375993Phase 1Enrolling By Invitation

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

Role: lead

NCT07100873Phase 1Recruiting

A Phase 1 Study of ADI-001 in Rheumatoid Arthritis

Role: lead

NCT06480565Phase 1Active Not Recruiting

A Phase 1/2 Trial of ADI-270 in ccRCC

Role: lead

NCT04735471Phase 1Terminated

A Phase 1 Study of ADI-001 in B Cell Malignancies

Role: lead

All 5 trials loaded